புற்றுநோய் ஆஃப் சிறுநீர்ப்பை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புற்றுநோய் ஆஃப் சிறுநீர்ப்பை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புற்றுநோய் ஆஃப் சிறுநீர்ப்பை Today - Breaking & Trending Today

IDSA Reverses on Actemra; 500K COVID Deaths; J&J Says 20M Vax Doses by Spring

Note that some links may require registration or subscription.
The Infectious Diseases Society of America (IDSA) changed course on tocilizumab (Actemra), and now conditionally recommends the IL-6 blocker on top of standard care for hospitalized patients with worsening severe or critical COVID-19.
President Biden ordered flags to be flown at half-mast until Friday to mark the half-million lives lost to COVID-19; the grim marker comes a little over a year since the first known death from COVID-19. (
Reuters)
As of 8 a.m. ET on Tuesday, the unofficial COVID-19 toll in the U.S. included 28,191,010 cases and 500,441 deaths, up 56,207 and 1,540, respectively, since this time a day ago. ....

United States , South Africa , New York , New York Times , University Of Texas Rio Grande Valley , Washington Post , Infectious Diseases Society Of America , Infectious Diseases Society , Texas Rio Grande Valley , Gastrointestinal Hemorrhage , Alveolar Hypoventilation , Gtraumatic Injury , Carcinoma Of Bladder , ஒன்றுபட்டது மாநிலங்களில் , புதியது யார்க் , புதியது யார்க் முறை , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ரியோ கிராண்டே பள்ளத்தாக்கு , வாஷிங்டன் போஸ்ட் , தொற்று நோய்கள் சமூகம் ஆஃப் அமெரிக்கா , தொற்று நோய்கள் சமூகம் , டெக்சாஸ் ரியோ கிராண்டே பள்ளத்தாக்கு , அதிர்ச்சிகரமான காயம் , புற்றுநோய் ஆஃப் சிறுநீர்ப்பை ,

Survival Boost in Bladder Cancer With Antibody-Drug Conjugate

email article
The antibody-drug conjugate (ADC) enfortumab vedotin significantly improved overall survival (OS) in patients with advanced, previously treated bladder cancer, a large randomized trial showed.
Median OS improved from about 9 months with standard chemotherapy to almost 13 months with enfortumab vedotin-ejfv (Padcev). Median progression-free survival also improved significantly with the ADC, from 3.71 to 5.55 months.
The incidence of treatment-related adverse events (TRAEs) was similar between treatment groups, including grade ≥3 TRAEs, reported Thomas Powles, MD, of Barts Cancer Center and Queen Mary University in London, during the virtual Genitourinary Cancers Symposium (GuCS). The results were published simultaneously in the
Enfortumab vedotin is the first drug beyond chemotherapy and immune therapy to show a significant survival advantage in previously treated advanced urothelial cancer, said Powles. This is a big step in the right dire ....

New York , United States , City Of , United Kingdom , Arjun Vasant Balar , Charles Bankhead , Thomas Powles , Langone Health , Queen Mary University , Barts Cancer Center , Perlmutter Cancer Center , Genitourinary Cancers Symposium , New England Journal , Medpage Today , Carcinoma Of Bladder , Malignant Tumor Of Urinary Bladder , Mass Of Body Structure , Neoplastic Disease , Malignant Adenomatous Neoplasm , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , அர்ஜுன் வசந்த பாலார் , சார்லஸ் வங்கித் தலை , லன்கொனே ஆரோக்கியம் ,